Advances in structure-based vaccine design.

Despite the tremendous successes of current vaccines, infectious diseases still take a heavy toll on the global population, and that provides strong rationale for broadening our vaccine development repertoire. Structural vaccinology, in which protein structure information is utilized to design immunogens, has promise to provide new vaccines against traditionally difficult targets. Crystal structures of antigens containing one or more protection epitopes, especially when in complex with a protective antibody, are the launching point for immunogen design. Integrating structure and sequence information for families of broadly neutralizing antibodies (bNAbs) has recently enabled the creation of germline-targeting immunogens that bind and activate germline B-cells in order to initiate the elicitation of such antibodies. The contacts between antigen and neutralizing antibody define a structural epitope, and methods have been developed to transplant epitopes to scaffold proteins for structural stabilization, and to design minimized antigens that retain one or more key epitopes while eliminating other potentially distracting or unnecessary features. To develop vaccines that protect against antigenically variable pathogens, pioneering structure-based work demonstrated that multiple strain-specific epitopes could be engineered onto a single immunogen. We review these recent structural vaccinology efforts to engineer germline-targeting, epitope-specific, and/or broad coverage immunogens.

[1]  R. Varadarajan,et al.  Design of a Non-glycosylated Outer Domain-derived HIV-1 gp120 Immunogen That Binds to CD4 and Induces Neutralizing Antibodies* , 2010, The Journal of Biological Chemistry.

[2]  J. Whittle,et al.  Structural and genetic basis for development of broadly neutralizing influenza antibodies , 2012, Nature.

[3]  M. Bolognesi,et al.  Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections , 2011, Proceedings of the National Academy of Sciences.

[4]  Jamie K. Scott,et al.  Complex binding sites made to order , 2012, Nature Biotechnology.

[5]  Shuzhao Li,et al.  Systems vaccinology: learning to compute the behavior of vaccine induced immunity , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[6]  Ron Diskin,et al.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.

[7]  J. Heeney,et al.  Viruses as vaccine vectors for infectious diseases and cancer , 2010, Nature Reviews Microbiology.

[8]  D. Burton Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[9]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[10]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[11]  D. Montefiori,et al.  Design of an Escherichia coli Expressed HIV-1 gp120 Fragment Immunogen That Binds to b12 and Induces Broad and Potent Neutralizing Antibodies , 2013, The Journal of Biological Chemistry.

[12]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[13]  L. Stamatatos,et al.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.

[14]  Xavier Daura,et al.  Exploiting Antigenic Diversity for Vaccine Design , 2010, The Journal of Biological Chemistry.

[15]  B. Graham,et al.  DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases , 2009, Human vaccines.

[16]  S. Plotkin Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[17]  T. Schlake,et al.  Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection , 2012, Nature Biotechnology.

[18]  S. Koide,et al.  Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. , 2005, Journal of molecular biology.

[19]  Jens Meiler,et al.  ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. , 2011, Methods in enzymology.

[20]  T. Kepler,et al.  Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies , 2013, The Journal of experimental medicine.

[21]  J. Mascola,et al.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials , 2011, The Lancet Infectious Diseases.

[22]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[23]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[24]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[25]  C. Donati,et al.  Reverse vaccinology in the 21st century: improvements over the original design , 2013, Annals of the New York Academy of Sciences.

[26]  R. Varadarajan,et al.  Design of Escherichia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge , 2012, Journal of Virology.

[27]  Ryo Takano,et al.  A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. , 2010, Antiviral research.

[28]  A MarioCalvo,et al.  Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .

[29]  Q. Sattentau,et al.  Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens , 2012, Nature Biotechnology.

[30]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[31]  J. Julien,et al.  Structural insights into key sites of vulnerability on HIV‐1 Env and influenza HA , 2012, Immunological reviews.

[32]  Jeannette Adu-Bobie,et al.  Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.

[33]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[34]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[35]  M. A. Olson,et al.  Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen , 2011, Proteins.

[36]  D. Granoff Review of meningococcal group B vaccines. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Nussenzweig,et al.  Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120 , 2012, Retrovirology.

[38]  D. Burton,et al.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions , 2010, Proceedings of the National Academy of Sciences.

[39]  R. Rappuoli,et al.  Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity , 2011, Science Translational Medicine.

[40]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[41]  Eva K. Lee,et al.  Systems Biology of Seasonal Influenza Vaccination in Humans , 2011, Nature Immunology.

[42]  S. Ozawa,et al.  Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. , 2012, Vaccine.

[43]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[44]  L. Stamatatos,et al.  Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity , 2009, Journal of Virology.

[45]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[46]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[47]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[48]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[49]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[50]  D. Baker,et al.  Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.

[51]  M. Slifka,et al.  Wanted, dead or alive: new viral vaccines. , 2009, Antiviral research.

[52]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[53]  Yih-En Andrew Ban,et al.  Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.

[54]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[55]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[56]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[57]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[58]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[59]  D. Baker,et al.  Computational Design of High-Affinity Epitope Scaffolds by Backbone Grafting of a Linear Epitope , 2011, Journal of Molecular Biology.

[60]  E. Reinherz,et al.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization , 2011, Nature Structural &Molecular Biology.

[61]  J. Sodroski,et al.  Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.

[62]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[63]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[64]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[65]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[66]  D. Baker,et al.  Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold , 2011, Science.

[67]  V. Brusic,et al.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.

[68]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[69]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[70]  Nimrod D. Rubinstein,et al.  Computational characterization of B-cell epitopes. , 2008, Molecular immunology.

[71]  S. Reed,et al.  Role of adjuvants in modeling the immune response , 2010, Current opinion in HIV and AIDS.

[72]  A. West,et al.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.

[73]  I. Messaoudi,et al.  Protective immunity following vaccination: How is it defined? , 2008, Human vaccines.

[74]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[75]  Rino Rappuoli,et al.  Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.

[76]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[77]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[78]  D. Burton,et al.  Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.

[79]  Shan Lu Heterologous prime-boost vaccination. , 2009, Current opinion in immunology.

[80]  S. Reed,et al.  Targeting TLRs Expands the Antibody Repertoire in Response to a Malaria Vaccine , 2011, Science Translational Medicine.

[81]  Magdalini Moutaftsi,et al.  Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140 , 2012, PloS one.

[82]  R. Rappuoli,et al.  Structural vaccinology starts to deliver , 2012, Nature Reviews Microbiology.

[83]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[84]  J. Mascola,et al.  Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 , 2012, Journal of Virology.

[85]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[86]  J. Mascola,et al.  Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region , 2009, Journal of Virology.

[87]  Q. Sattentau,et al.  Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants , 2012, PloS one.

[88]  S. Plotkin Correlates of Vaccine-Induced Immunity , 2008 .